Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

LITESPARK-012 Trial Does Not Meet Primary End Point for Advanced RCC Group

Summary by cancernetwork.com
The safety profiles of the pembrolizumab-based combination regimens were consistent with those observed in previously reported studies.

3 Articles

Hastings TribuneHastings Tribune
Reposted by
Joplin GlobeJoplin Globe
Center

Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)

RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)--Apr 21, 2026-

·Nebraska, United States
Read Full Article
cancernetwork.comcancernetwork.com

LITESPARK-012 Trial Does Not Meet Primary End Point for Advanced RCC Group

The safety profiles of the pembrolizumab-based combination regimens were consistent with those observed in previously reported studies.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Hastings Tribune broke the news in Nebraska, United States on Tuesday, April 21, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Rahway icon

Rahway

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal